SCHEMBL4465185

SCHEMBL4465185

c1ccc(CN2CCC(c3cn[nH]c3)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
DRD2 P14416 7/20 0.53
DRD4 P21917 5/20 0.50
DRD3 P35462 5/20 0.50
CCR5 P51681 3/20 0.50
CXCR4 P61073 1/20 0.50
ACHE P22303 1/20 0.50
CCR3 P51677 1/20 0.49
SIGMAR1 Q99720 1/20 0.47
ROCK2 O75116 1/20 0.47
CCR2 P41597 1/20 0.47
ROCK1 Q13464 1/20 0.47
HPGDS O60760 1/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
SCN9A Q15858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31572354 0.85 ALDH1A1 (0.52) DRD2DRD4DRD3ROCK2CCR2
SCHEMBL1002852 0.80 MEN1 (0.81) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL31572319 0.79 FUCA1 (0.46)
SCHEMBL31313847 0.78 CNR2 (0.59) DRD4
SCHEMBL19463240 0.77 ROCK2 (0.61) KMT2ADRD2DRD4DRD3ACHE
SCHEMBL2569983 0.75 TRPV6 (0.64) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL7571134 0.74 MEN1 (0.88) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL9070278 0.74 MEN1 (0.67) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL27984545 0.74 HSD11B1 (0.41) DRD2
SCHEMBL11453030 0.73 POLB (0.67) MEN1KMT2ADRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491737-B2 Heterarylpiperidine modulators of chemokine receptor activity MERCK & CO., INC. (US) 2009-02-17 US disclosed
EP-1558599-A4 HETEROARYLPIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2007-06-27 EP disclosed
US-20050250781-A1 Heterarylpiperidine modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2005-11-10 US disclosed
EP-1558599-A2 HETEROARYLPIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2005-08-03 EP disclosed
WO-2004041777-A2 HETEROARYLPIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250781-A1 Heterarylpiperidine modulators of chemokine receptor activity CCR1, CCR2, CCRL2 MEN1 4619/4885KMT2A 3762/4885DRD2 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.